GlassScriptPhysician profile
Barry S Coller
NPI 1043227416
$7,929,520.80
in general payments reported to CMS, 2019-2025
2 companies · $63K in 2025
The $63K reported for 2025 was more than what 95% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.3M · 2020: $1.3M · 2021: $1.4M · 2022: $1.3M · 2023: $1.4M · 2024: $1.1M · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.6M · Consulting Fee: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,566,452.01 |
| Consulting Fee | $3,230.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Instrumentation Laboratory Company | $7,926,290.80 | 2019-2025 | |
| Chugai Pharmaceutical Co., LTD. | $3,230.00 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Coller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.